Michael O' Rourke , CEO Re-Vana Therapeutics, discusses positioning Re-Vana as a long-term platform partner by leveraging its sustained-delivery hydrogel technologies to support both internally developed assets and external pharma collaborations.
Michael O'Rourke
Advertisement
Articles by Michael O'Rourke
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026: Bristol Myers Squibb Focuses on the Next Decade
2
J.P. Morgan 2026: Pfizer’s Pivot from Covid to Pipeline Execution
3
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
4
Pharmaceutical Executive Daily: Johnson & Johnson Continues $55 Billion Manufacturing Investment
5